NASDAQ IPO Update

11 March 2014

Akers Biosciences, Inc.

("ABI" or the "Company")

NASDAQ IPO Update

Akers Biosciences, Inc. (AIM:AKR, NASDAQ:AKER), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that, further to the Company's announcement on 23 January 2014, the representatives of the underwriters have not taken up their 45-day option to purchase up to 409,050 additional common shares of no par value at a price of $5.50 per share. Accordingly, no further Common Shares are due to be issued on either NASDAQ or AIM.

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point‐of‐care screening and testing products designed to bring health status information, both rapidly and directly, to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state‐of‐the‐art rapid diagnostic assays can be performed virtually anywhere, in minutes, since time is always of essence. ABI is aligned with high volume medical product distributors to help facilitate the Company's growth into a major, worldwide competitor in the field of rapid diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

Enquiries:

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

Antony Legge or James Thomas (Nomad)

Martin Lampshire (Broker)

Daniel Stewart & Company plc

Tel. +44 (0)20 7776 6550

Ben Simons

Vigo Communications

Tel. +44 (0) 20 7016 9574